NovoCure (NVCR) reported a Q3 loss Wednesday of $0.28 per diluted share, narrower than a loss of $0.46 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.33.
Net revenue for the quarter ended Sept. 30 was $155.1 million, up from $127.3 million a year earlier.
Analysts surveyed by Capital IQ expected $144 million.
Price: 16.53, Change: -0.09, Percent Change: -0.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。